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CORRESPONDENCE
Letters to the Editor
The Effect of
Drug-Eluting Stents on
Collateral Coronary Flow
I read with great interest the article by Meier et al. (1) published
in the previous issue of the Journal. The article seems to report
another, previously unappreciated, adverse effect of the use of
drug-eluting stents (DES): impairment of coronary collateral
function. Despite the large study population and the elegant
well-validated method of measurement of collateral flow (2), we
remain very skeptical that this study truly proves its main conclusion.
After stent implantation, there is no stimulus for collateral
development because the main factors promoting its growth
(regional ischemia and the pressure gradient between poststenotic
artery and other normal or prestenotic coronary arterial segments)
are abolished. Conceptually, it is difficult to understand how an
extremely small amount of antiproliferative/cytotoxic medication
released downstream of the site of stent implantation can affect
quiescent endothelial cells in collapsed vessels with no flow. The
elution profile of the DES is so short that it is unconceivable to
expect a persistent drug release months after implantation, when
collateral neoformation may occur in response to severe restenosis.
A possible explanation for the difference observed and a sug-
gestion for data reanalysis comes from a more careful observation
of Figure 2: both groups seem to cluster at the bottom of the
collateral flow index range, suggesting a non-normal distribution
of the study population. Should a nonparametric test such as the
Wilcoxon signed rank test for paired data be used, the results of the
analysis could change.
The most likely reason for the high collateral flow index
observed in some patients with bare-metal stents (BMS) is the
presence of a more severe degree of restenosis in these patients.
Even though a similar average percent diameter stenosis is reported
on angiography, this is not sufficient to indicate an equivalent
functional severity in the 2 populations. The typical pattern of
in-stent restenosis after BMS implantation is diffuse proliferation,
as opposed to focal restenosis in DES, often at the edges of the
stent (3). If available, comparison of fractional flow reserve in the
2 groups at follow-up is a better marker of hemodynamic severity
(4) and would greatly help to clarify the cause of the observed
difference in collateral flow index.
Assuming that a “statistically significant” difference in collateral
flow index between the BMS and the DES groups truly exists, this
difference is unlikely to be clinically relevant. The collateral flow
index was so low in the majority of patients regardless of the type
of stent implanted, to be incompatible with myocardial viability in
the territory of distribution of the stented artery should an acute
occlusion, for instance a thrombosis, suddenly develop.
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Drug-Eluting Stent
Implantation and Coronary
Collateral Growth Attenuation:
Is Drug the Only Culprit?
In a recent issue of the Journal, Meier et al. (1) presented the
results of a physiological study designed to compare coronary flow
index in patients after bare-metal stent (BMS) or drug-eluting
stent (DES) implantation. They concluded that collateral function,
6 months after coronary stenting, with a DES is 30% to 40% lower
compared with a BMS. The authors hypothesized that their
findings might be related, in part, to the antiangiogenic properties
of DES through an inhibition of endothelial growth factors and
cytokines. Globally, reduced collateral formation may have a
negative influence on ischemic burden, particularly in the event of
acute thrombosis.
Although this study highlights a potentially new and important
downside of DES utilization, its results must be carefully analyzed
and interpreted in a broader clinical context. In fact, the patient
population selected in the DES group had a remarkably high
degree of restenosis after 6 months, as evidenced by coronary
angiographic data, showing an average of 45% in-stent diameter
stenosis in the 2 matched groups. Such a high level of restenosis 6
months after DES implantation is rarely observed in clinical
practice. Therefore, it can be hypothesized that by matching BMS
and DES patients for in-stent stenosis severity, Meier et al.
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(1) have inadvertently selected a subpopulation of DES patients
more prone to restenosis. Therefore, it seems that these patients
exhibited resistance to the antiproliferative and immunosuppres-
sive drugs released by DES. Consequently, it is plausible that this
subpopulation expresses various biological factors that may also
reduce the ability to generate collateral vessels. Hence, it may be
premature to consider DES as the leading factor contributing to
reduced collateral formation, until a study using widely patent
DES and BMS confirms this.
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Reply
We thank, respectively, Drs. di Mario and Dimopoulos and Drs.
Parent and Rinfret for their comments on our work (1). In fact, it
was conceived on the basis of experimental and clinical evidence
suggesting that local rapamycin or paclitaxel could have an adverse
effect on circulating monocytes (2), respectively, that coronary
endothelial function in humans is compromised up- as well as
downstream of the stent eluting such drugs (3,4). Thus, the
“broader context” requested by Parent and Rinfret actually incited
the study. It is, indeed, the case that the restenosis severity in the
stented segment was pronounced, and that the question may be
raised whether our study population is representative for all
patients receiving drug-eluting stents (DES). In the context of a
rather prominent in-stent restenosis, the reasoning by Parent and
Rinfret can even be followed to the point where they hypothesize
“resistance to the antiproliferative and immunosuppressive drugs”
in the DES group. However, to link the proposed opposition to
antiproliferation with impaired collateral growth is, even semanti-
cally, an oxymoron. This is because all the evidence of the past 40
years has very convincingly conveyed 1 message: collateral growth
is intimately tied to inflammatory (i.e., proliferative) processes (5).
It is correct that after stent implantation, there is no stimulus for
collateral development. However, our study has not focused on
stimuli, but on potential anti-stimuli of collateral growth. Further-
more, rapamycin and paclitaxel have been shown by independent
groups to elicit an adverse effect on endothelial function both up-
and downstream of the implantation site. Drs. di Mario and
Dimopoulos also claim that alternative ways of data analysis would
have probably uncovered their frail character. First, to apply the
proposed nonparametric statistical analysis provides 38 higher
collateral flow index ranks in the bare-metal stent (BMS) than in
the DES group, and 21 lower ranks (p  0.0020). Second, it was
maybe not pointed out clearly enough that ours was a study with
a matched design for stenosis severity at the time of follow-up. In
this context, Table 3 of our article has already provided the
fractional flow reserve values (0.828  0.184 vs. 0.838  0.177)
asked for by di Mario and Dimopoulos, thus documenting that the
paired stenotic lesions were well comparable hemodynamically.
Third, Table 3 of our article has displayed even more information
(i.e., electrocardiogram [ECG] data against the argument that the
CFI difference between the groups “is unlikely to be clinically
relevant”: signs of ischemia during coronary balloon occlusion on
intracoronary ECG were present in 33 of 60 patients in the BMS
group, but in 50 of 60 patients of the DES group). The magnitude
of ECG ST-segment elevation during a temporary occlusion has
been and is employed as a surrogate marker for infarct size in case
of a permanent occlusion for decades. As di Mario and Dimopou-
los certainly know, infarct size is gradually and not binarily
influenced by the product of coronary occlusion time, myocardial
area at risk, oxygen consumption at and during the time of
occlusion, and the inverse of collateral supply.
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